Hormone Therapy: Expert For Relief Of Menopause Symptoms Or For Gamble Of Os Loss, Simply No Resultant On Gist Disease
Saturday, March 10, 2018
Edit
Heart illness is yet the issue 1 killer of U.S. of A. women, too hormone therapy remains a tiptop handling for menopause symptoms. Influenza A virus subtype H5N1 novel study connects these 2 facts to demonstrate picayune upshot of hormone therapy on artery thickness every bit a precursor to midpoint disease. Study results are published online today inwards Menopause, the magazine of The North American Menopause Society (NAMS).
According to the American Heart Association, midpoint illness is responsible for 1 inwards iii deaths of U.S. of A. women each year. That agency close 1 adult woman dies every minute. Statistics similar these drive a continued involvement inwards the medical champaign to study run a peril factors that may touching on the incidence of midpoint disease. This includes the ongoing ground regarding the upshot of hormone therapy on the progression of cardiovascular disease.
The well-known Kronos Early Estrogen Prevention Study (KEEPS) was designed to compare the effects of lower doses of either oral conjugated equine estrogens (CEE) or transdermal estradiol on the progression of atherosclerosis (hardening too thickening of the arteries), the most mutual campaign of midpoint attacks too strokes. After iv years of therapy, no differences inwards artery thickness were detected alongside the oral CEE-, transdermal estradiol-, too placebo-treated groups. In this novel study, a subgroup of KEEPS participants were farther evaluated for 3 years later the initial study.
The results of the follow-up study look inwards the article "Changes inwards carotid artery intima-media thickness 3 years later cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study." Study results demonstrate that the cessation of hormone therapy at the lower doses did non accelerate changes inwards the thickness of the arteries.
"In the KEEPS trial, depression doses of hormone therapy (oral or transdermal) given for iv years about menopause did non meliorate carotid artery intima-media thickness (CIMT), too this study shows no rebound upshot on progression of CIMT later stopping the hormones," says medico JoAnn Pinkerton, executive managing director of NAMS. "In contrast, the Early Versus Late Intervention Trial With Estradiol (ELITE) industrial plant life benefits on CIMT when hormone therapy was given early on simply non when started to a greater extent than than 10 years from menopause. The primary indication for the purpose of hormone therapy should live on for relief of bothersome menopause symptoms or for those at elevated run a peril of os loss. There may live on beneficial effects on reduction of midpoint disease, simply it should non live on used for its prevention."
Sumber http://healthnewsreport.blogspot.com/
The well-known Kronos Early Estrogen Prevention Study (KEEPS) was designed to compare the effects of lower doses of either oral conjugated equine estrogens (CEE) or transdermal estradiol on the progression of atherosclerosis (hardening too thickening of the arteries), the most mutual campaign of midpoint attacks too strokes. After iv years of therapy, no differences inwards artery thickness were detected alongside the oral CEE-, transdermal estradiol-, too placebo-treated groups. In this novel study, a subgroup of KEEPS participants were farther evaluated for 3 years later the initial study.
The results of the follow-up study look inwards the article "Changes inwards carotid artery intima-media thickness 3 years later cessation of menopausal hormone therapy: follow-up from the Kronos Early Estrogen Prevention Study." Study results demonstrate that the cessation of hormone therapy at the lower doses did non accelerate changes inwards the thickness of the arteries.
"In the KEEPS trial, depression doses of hormone therapy (oral or transdermal) given for iv years about menopause did non meliorate carotid artery intima-media thickness (CIMT), too this study shows no rebound upshot on progression of CIMT later stopping the hormones," says medico JoAnn Pinkerton, executive managing director of NAMS. "In contrast, the Early Versus Late Intervention Trial With Estradiol (ELITE) industrial plant life benefits on CIMT when hormone therapy was given early on simply non when started to a greater extent than than 10 years from menopause. The primary indication for the purpose of hormone therapy should live on for relief of bothersome menopause symptoms or for those at elevated run a peril of os loss. There may live on beneficial effects on reduction of midpoint disease, simply it should non live on used for its prevention."